07 June 2022 | News
New Xevo G3 quadrupole time-of-flight mass spectrometer that is up to 10X more sensitive than its predecessori for qualitative and quantitative analyses of challenging molecules
Image credit: businesswire
Waters Corporation has unveiled new instruments, software and product enhancements to drive drug discovery and development. The products include the new Xevo G3 quadrupole time-of-flight (QTof) mass spectrometer, CONFIRM Sequence - a new oligonucleotide sequencing confirmation app for the waters_connect software platform and an electrospray ionization source for the high-resolution Waters SELECT SERIES Multi-Reflecting Time of Flight (MRT) mass spectrometer.
The new Xevo G3 QTof system is a high-performance, benchtop mass spectrometer for characterizing and quantifying molecules in applications such as biotherapeutics, forensics, metabolite identification, metabolomics and extractables and leachables.
The CONFIRM Sequence app on the waters_connect software platform helps scientists using a Waters LC-MS System to confirm the nucleic acid sequence of therapeutics and identify impurities that could compromise product safety and efficacy.
The Waters SELECT SERIES MRT System is now compatible with UPLC-MS with an available electrospray ionization (ESI) source. Coupling the high resolution MRT System with the ESI source enables scientists to accurately resolve and measure low (<200 ppb) concentrations of sample analytes at UPLC acquisition speeds for metabolomics, metabolite identification or peptide mapping applications.